WHO announced in October 2019 that pyrimethamine (WHOAPI-371) has been prequalified by the WHO Prequalification Team as an API.

WHO performs prequalification of APIs to assist in the production of high quality medicines. Its process consists of a comprehensive evaluation, including checking the API Master File to assure compliance with WHO standards and assessing manufacturing sites to confirm good manufacturing practice (GMP) standards are being met.

Pyrimethamine is a small molecule drug used to treat parasitic diseases including toxoplasmosis. It is typically given with follinic acid to reduce toxic effects.

Pyrimethamine has been prequalified by WHO for use in finished pharmaceutical products for the treatment of malaria. The prequalified product is produced by India-based Macleods Pharmaceuticals.

Related articles
WHO prequalifies first generic hepatitis C drug

WHO to launch prequalification programme for biosimilars

WHO prequalification programme for APIs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.